Meeting
2024 ASCO Annual Meeting
Preliminary experience of ex-vivo expanded allogeneic universal donor TGFβi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial.
Presenter
Mark A. Ranalli, MD
Nationwide Children's Hosp
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Pediatric Oncology I
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT04211675
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 10005)
DOI
10.1200/JCO.2024.42.16_suppl.10005
Abstract #
10005
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2016 ASCO Annual Meeting
ANBL1221: A Phase II Randomized Trial of Irinotecan and Temozolomide with Temsirolimus or Dinutuximab in Children with Refractory, Relapsed or Progressive Neuroblastoma: A Report From the Children's Oncology Group
Speaker: Rajen Mody, MD, MS
Videos & Slides
2023 ASCO Annual Meeting
Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.
Speaker: Selim Corbacioglu, MD PhD
Speaker: Panel Discussion
Videos & Slides
2020 ASCO Virtual Scientific Program
Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial.
Speaker: Keith Wheatley, D.Phil